Best Peptide Stacks: Complete Stacking Guide [Charts & Protocols]

Peptides that target different receptors can be injected at the same time. BPC-157 and TB-500 work through entirely separate mechanisms, so simultaneous injection is standard practice.

GH secretagogues (ipamorelin, CJC-1295) require an empty stomach. Injecting them within 60 minutes of a meal blunts growth hormone release by up to 80% (Nass et al., J Clin Endocrinol Metab, 2008). Schedule these before bed or at least 90 minutes after your last meal.

Sample daily timing for a three-peptide stack (BPC-157 + TB-500 + Ipamorelin):

The short answer: it depends on the peptides. BPC-157 and TB-500 are commonly drawn into the same syringe and injected together. Both are stable in bacteriostatic water and do not interact chemically.

Peptides from different classes should generally be kept in separate syringes. Mixing GH secretagogues with healing peptides in one syringe is not well-studied. The risk is not toxicity; it is degradation. Some peptides alter the pH of the solution, potentially denaturing the other compound before it reaches your tissue.

Safe to combine in one syringe: BPC-157 + TB-500, GHK-Cu + BPC-157 + TB-500 (the GLOW blend).

Use separate syringes: Ipamorelin + BPC-157, CJC-1295 + any healing peptide, semaglutide + anything else.

Rotate injection sites to prevent lipodystrophy (fat tissue changes at the injection site). Use at least four sites and cycle through them systematically.

Subcutaneous injection sites: left abdomen, right abdomen, left thigh, right thigh. Some users add the upper arm as a fifth site.

For localized healing (knee tendonitis, shoulder injury), inject BPC-157 subcutaneously near the injury site. TB-500 works systemically, so its injection location does not affect which tissue it reaches. For BPC-157 knee injection technique, see where to inject BPC-157 for knee pain.

Use the Peptide Reconstitution Calculator to determine your exact draw volume before injecting.

Loading Phase (Weeks 1-4):

Maintenance Phase (Weeks 5-8):

Protocol notes: - TB-500 requires 4-6 weeks to reach tissue saturation. Do not judge results before week 4. - BPC-157 provides faster initial relief (often within 7-14 days) because it acts locally. - For a 200 lb male, the BPC-157 dosage calculator recommends 500 mcg daily. See the full breakdown at BPC-157 dosage for a 200 lb male. - Total cycle cost: approximately $80-150 depending on source and vial size. Use the Peptide Cost Calculator to estimate your specific protocol. - Store reconstituted vials properly. Potency degrades after 28-30 days in the refrigerator. See how long reconstituted peptides last and how to store peptides.

GHK-Cu adds a third repair mechanism to the Wolverine Stack. While BPC-157 builds vessels and TB-500 mobilizes cells, GHK-Cu delivers the copper required for lysyl oxidase to cross-link collagen fibers into durable tissue (Pickart et al., BioMed Res Int, 2012). Without this cross-linking step, new collagen is fragile and prone to re-injury.

Triple Healing Stack Protocol:

GHK-Cu also modulates over 4,000 human genes, suppressing IL-6 and TNF-alpha while activating antioxidant defenses. Users report enhanced skin quality and faster scar resolution as additional benefits.

For the pre-mixed version of this stack, see the GHK-Cu + BPC-157 + TB-500 blend dosage guide. For GHK-Cu's additional benefits, including collagen stimulation and hair follicle support, see GHK-Cu for hair growth.

This is the gold standard GH secretagogue stack. Ipamorelin is a selective GH secretagogue that triggers pituitary GH release without raising cortisol or prolactin (Raun et al., Eur J Endocrinol, 1998). CJC-1295 DAC extends the GH release window from minutes to hours through its Drug Affinity Complex, which binds to albumin and prolongs half-life to 6-8 days (Teichman et al., J Clin Endocrinol Metab, 2006).

Ipamorelin fires the GH pulse. CJC-1295 DAC keeps the pulse elevated. Together, they produce sustained GH elevation that a single compound cannot achieve.

Protocol:

Cycle length: 12 weeks on, 4 weeks off. Extended use beyond 16 weeks may desensitize GH receptors.

Expected outcomes: Improved sleep quality within 1-2 weeks. Visible body composition changes (reduced fat, increased lean mass) by weeks 6-8. Enhanced recovery between training sessions.

Critical rule: Inject ipamorelin on an empty stomach. Food intake, particularly carbohydrates and fats, suppresses ghrelin-mediated GH release by up to 80% (Nass et al., J Clin Endocrinol Metab, 2008). Wait at least 90 minutes after eating. Most users inject 15-30 minutes before sleep.

For complete dosage charts across all peptides, see the peptide dosage chart.

Follistatin-344 binds myostatin, the protein that limits muscle growth. Blocking myostatin removes the genetic ceiling on muscle fiber hypertrophy. This is a more advanced addition to the ipamorelin + CJC-1295 stack.

Protocol:

Follistatin-344 cycles are kept short (10-30 days) due to the compound's potent effect on follicle-stimulating hormone (FSH), which can temporarily affect fertility in men. Full protocol details and safety considerations are covered in the follistatin-344 dosage guide.

For BPC-157's indirect role in supporting muscle recovery through tendon and tissue repair, see BPC-157 for muscle growth.

Semaglutide and tirzepatide produce dramatic weight loss (15-22% body weight over 72 weeks per the SURMOUNT trials) (Jastreboff et al., NEJM, 2022). The main limitations are GI side effects: nausea, constipation, and slowed gastric emptying.

BPC-157 is commonly added to GLP-1 stacks for gastroprotective effects. BPC-157 accelerates gastric mucosal healing and modulates nitric oxide pathways in the gut. Users report reduced nausea and fewer GI complications when running BPC-157 alongside semaglutide or tirzepatide.

Sample protocol:

Caution: Do not combine semaglutide with tirzepatide. Both activate GLP-1 receptors. Running them together doubles GI side effects without additional fat loss benefit. Choose one. For a detailed comparison, see retatrutide vs. tirzepatide.

For semaglutide-specific dosing and reconstitution, see the semaglutide dosage chart in mL.

MOTS-c is a mitochondrial-derived peptide that mimics the metabolic effects of exercise at the cellular level. It activates AMPK, increases glucose uptake into skeletal muscle, and improves insulin sensitivity (Lee et al., Cell Metab, 2015). In mouse studies, MOTS-c prevented diet-induced obesity and reversed age-dependent insulin resistance.

MOTS-c does not replace exercise. It amplifies the metabolic adaptations that exercise produces. Users report enhanced endurance, faster recovery between cardio sessions, and measurable reductions in fasting glucose.

Protocol:

MOTS-c pairs well with virtually every other peptide on the compatibility chart. It targets mitochondrial metabolism, a pathway that no other peptide in this guide activates. For complete MOTS-c dosing protocols, see the MOTS-c dosage guide.

Tesamorelin is a growth hormone releasing hormone (GHRH) analog FDA-approved for HIV-associated lipodystrophy. It specifically reduces visceral adipose tissue (the deep abdominal fat surrounding organs) by an average of 15-18% over 26 weeks in clinical trials.

Unlike ipamorelin, tesamorelin directly stimulates the GHRH receptor rather than working through ghrelin pathways. This makes it a complementary addition to an ipamorelin stack for users targeting both subcutaneous and visceral fat.

Protocol:

Tesamorelin can be stacked with MOTS-c for a dual-mechanism fat loss approach: tesamorelin mobilizes visceral fat through GH-mediated lipolysis, while MOTS-c increases mitochondrial fat oxidation. For complete dosing protocols, see tesamorelin dosage for fat loss. An alternative GH-pathway approach is sermorelin for fat loss, which works through a similar GHRH mechanism at lower cost.

GHK-Cu reverses age-related decline in collagen and extracellular matrix integrity. It modulates over 4,000 genes involved in tissue remodeling, suppresses pro-inflammatory cytokines (IL-6, TNF-alpha), and activates proteasome and antioxidant pathways (Pickart et al., BioMed Res Int, 2012). Serum GHK-Cu levels drop from 200 ng/mL at age 20 to 80 ng/mL by age 60. Supplementation restores the signaling environment of younger tissue.

Thymosin Alpha-1 (TA-1) addresses the immune side of aging. The thymus gland shrinks with age, reducing naive T-cell production. TA-1 activates dendritic cells, enhances T-cell maturation, and modulates the Th1/Th2 immune balance. It has been approved in over 35 countries for hepatitis B and as an immune adjuvant. For a complete overview, see thymosin alpha-1 benefits.

Protocol:

This stack produces visible skin quality improvements within 3-4 weeks (fewer fine lines, faster wound healing) and measurable immune marker improvements within 6-8 weeks.

Epitalon (epithalon) is a synthetic tetrapeptide based on epithalamin, a pineal gland extract. Its primary mechanism is telomerase activation. In cell culture studies, epitalon increased telomerase activity and extended the lifespan of human fetal fibroblasts by 44% compared to controls.

Epitalon also normalizes melatonin secretion patterns that degrade with age, improving sleep architecture. Better sleep drives higher nocturnal GH output, creating a positive feedback loop for tissue repair.

Protocol:

Epitalon cycles are short because telomerase activation does not require chronic stimulation. Two to three cycles per year maintain telomere length without the theoretical risks of sustained telomerase upregulation.